Sanofi Drug Beats AbbVie's Blockbuster Humira in Human Trial

  • Sarilumab tested in head-to-head trial with AbbVie's Humira
  • U.S. regulators set to decide on sarilumab in fourth quarter

Sanofi and Regeneron Pharmaceuticals Inc. said an experimental rheumatoid arthritis therapy helped patients more than AbbVie Inc.’s Humira in a late-stage trial.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.